Carrie-Lynn Langlais Furr, Ph.D., RAC, is a global regulatory affairs professional with more than 15 years of experience developing drug and biologic medicines. Furr is responsible for 7 FDA approvals (1 BLA, 6 NDAs), 16 INDs/CTAs and an orphan designation for a gene therapy.

Her experience includes developing biologic devices, virus-based therapies (AAV, bacteriophage [natural, engineered]), gene therapy (including CRISPR gene-editing technology), immunotherapy, and drugs for a range of indications and patients. Furr earned a Ph.D. in biochemistry and biophysics from Texas A&M University and holds Regulatory Affairs Certification from the Regulatory Affairs Professionals Society.